DrugPatentWatch Database Preview

Lannett Company Profile

« Back to Dashboard

What is the competitive landscape for LANNETT, and what generic alternatives to LANNETT drugs are available?

LANNETT has one hundred and ninety-six approved drugs.

There is one US patent protecting LANNETT drugs.

Summary for Lannett

US Patents:	1
Tradenames:	144
Ingredients:	133
NDAs:	196
Patent Litigation for Lannett:	See patent lawsuits for Lannett
PTAB Cases with Lannett as petitioner:	See PTAB cases with Lannett as petitioner

Drugs and US Patents for Lannett

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lannett Co Inc	TEMOZOLOMIDE	temozolomide	CAPSULE;ORAL	203898-005	Feb 10, 2016	AB	RX	No	No
Lannett	VITAMIN D	ergocalciferol	CAPSULE;ORAL	080825-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Lannett Co Inc	DRONABINOL	dronabinol	CAPSULE;ORAL	201463-003	May 18, 2018	AB	RX	No	No
Lannett Co Inc	HYDROMORPHONE HYDROCHLORIDE	hydromorphone hydrochloride	TABLET;ORAL	077471-002	Dec 9, 2009	AB	RX	No	No
Lannett Co Inc	NIACIN	niacin	TABLET, EXTENDED RELEASE;ORAL	203899-001	Jun 16, 2017	AB	RX	No	No

Expired US Patents for Lannett

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lannett Co Inc	MYKROX	metolazone	TABLET;ORAL	019532-001	Oct 30, 1987	4,517,179

Paragraph IV (Patent) Challenges for LANNETT drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Extended-release Capsules	10 mg, 20 mg and 30 mg		2005-05-13
	Delayed-release Tablets	20 mg		2015-06-03
	Extended-release Capsules	40 mg		2007-03-15

International Patents for Lannett Drugs

Country	Document Number	Estimated Expiration
European Patent Office	2269605
European Patent Office	1328251
Australia	2001297011
Poland	361673
Poland	203828

Supplementary Protection Certificates for Lannett Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C0062	France		PRODUCT NAME: (A) DEXTROMETHORPHAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRATE DE DEXTROMETHORPHAN ET EN PARTICULIER LE MONOHYDRATE DE BROMHYDRATE DE DEXTROMETHORPHAN (B) QUINIDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE SULFATE DE QUINIDINE EN PARTICULIER LE DIHYDRATE DE SULFATE DE QUINIDINE; REGISTRATION NO/DATE: EU/1/13/833/001-003 20130626
C0032	Belgium		PRODUCT NAME: PANTOPRAZOL. NATR. SESQUIHYDRAS PANTOPRAZOLE; NAT. REGISTRATION NO/DATE: 127 IS 98 F 3 19960222; FIRST REGISTRATION: SE 12131 19940506
90027-7	Sweden		PRODUCT NAME: MONTELUKAST, R-(E)-1-1-3-2-(7-KLOR-2KINOLINYL)-ETENYL)-FENYL)-3-(2-(1-HYDROXI-1-METYLETYL)-FENYL)-PROPYL)-TIO)METYL)-CYKLOPROPANAETTIKSYRA, ELLER ETT FARMACEUTISKT GODDTAGBART SALT DAERAV, FOERETRAEDESVIS NATRIUMSALTET; NAT REG./DATE: 13944 19880111; FIRST REG.: FI EG 12766 19970825
C0041	France		PRODUCT NAME: CYCLO((4R)-4(2-AMINOETHYLCARBAMOYLOXY)-L-PROLYL-L-PHENYLGLYCYL-D-TRYPTOPHYL-L-LYSYL-4-O-BENZYL-L-TYROSYL-L-PHENYLALANYL-) : PASIREOTIDE, OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/12/753/001 20120424
C0004	France		PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Lannett
• Lannett Co Inc
• Lannett Holdings Inc